Bladder Cancer

Latest News

Enfortumab vedotin plus pembrolizumab improves survival in frontline urothelial cancer
Enfortumab vedotin plus pembrolizumab improves survival in frontline urothelial cancer

September 22nd 2023

The EV-302 trial is the confirmatory trial for the FDA’s accelerated approval of pembrolizumab plus enfortumab vedotin for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.

ADVANCED-2 trial launches exploring TARA-002 in NMIBC
ADVANCED-2 trial launches exploring TARA-002 in NMIBC

September 20th 2023

Oral APL-1202 shows promise for MIBC in phase 2 trial
Oral APL-1202 shows promise for MIBC in phase 2 trial

September 14th 2023

Novel intravesical gene therapy for NMIBC launches in select US clinics
Novel intravesical gene therapy for NMIBC launches in select US clinics

September 12th 2023

Phase 2/3 study launching of targeted therapy BT8009 in urothelial carcinoma
Phase 2/3 study launching of targeted therapy BT8009 in urothelial carcinoma

September 12th 2023

Video Series
Video Interviews
Podcasts
medical depiction of bladder cancer
Latest CME Events & Activities

2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers

View More

Community Practice Connections™: 23rd Annual International Lung Cancer Congress®

View More

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

View More

Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

View More

20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

9th Annual School of Gastrointestinal Oncology® (SOGO®)

Register Now!

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Register Now!

New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies

View More

Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies

View More

Medical Crossfire®: Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

23rd Annual International Congress on the Future of Breast Cancer® West

Register Now!

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

25th Annual International Lung Cancer Congress®

Register Now!

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

Community Practice Connections™: Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board

View More

More News

© 2023 MJH Life Sciences

All rights reserved.